Um zukunftsfähig zu sein, wurde unsere aktuelle Webseite für die neuesten Technologien entwickelt.
Daher können bei alten Browsern leider Probleme auftreten.
Damit die neue Börse-Online-Seite richtig funktioniert und Spaß macht, empfehlen wir Ihnen einen dieser aktuellen und kostenlosen Browser herunterzuladen:

DAX 15.473 -0,3%  MDAX 34.717 0,5%  Dow 35.603 0,0%  Nasdaq 15.490 0,7%  Gold 1.786 0,2%  TecDAX 3.780 0,8%  EStoxx50 4.156 -0,4%  Nikkei 28.892 0,6%  Dollar 1,1627 0,0%  Öl 84,3 -0,6% 

COCP 2,09$ (+56%)

Seite 1 von 2
neuester Beitrag: 07.10.21 08:25
eröffnet am: 25.02.20 16:17 von: Vassago Anzahl Beiträge: 30
neuester Beitrag: 07.10.21 08:25 von: Banani Leser gesamt: 4296
davon Heute: 2
bewertet mit 2 Sternen

Seite: Zurück
| 2 Weiter  

8435 Postings, 1592 Tage VassagoCOCP 2,09$ (+56%)

25.02.20 16:17


  • Umsatz 0,5 Mio. $ (alles für Q3/19)
  • Verlust 1,8 Mio. $
  • Cash 6 Mio. $
  • MK 87 Mio. $

Dann kam Corona, der Kurs stieg, das Management zog ein Offering durch:

  • 3,5 Mio. neue Aktien zu je 0,63$ = 2,2 Mio. $

Mal sehen, wann die nächste Kapitalerhöhung kommt...


2293 Postings, 1130 Tage up088-k News raus

04.03.20 16:05
$COCP. Current Report Filing (8-k)



Washington, D.C. 20549



Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 4, 2020

Cocrystal Pharma, Inc.

(Exact name of registrant as specified in its charter)

Delaware 001-38418 35-2528215
(State or other Jurisdiction

of Incorporation)


File Number)

(IRS Employer

Identification No.)

19805 N. Creek Parkway

Bothell, WA

(Address of principal executive offices) (Zip Code)

Registrant?s telephone number, including area code: (786) 459-1831

(Former name or former address, if changed since last report.):

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).

Emerging growth company [ ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class Trading Symbol(s) Name of each exchange on which registered
Common Stock COCP
The Nasdaq Stock Market LLC

(The Nasdaq Capital Market)

Item 7.01 Regulation FD Disclosure.

On March 4, 2020, Cocrystal Pharma, Inc. (the ?Company?) posted a presentation to its website. A copy of the Company?s presentation is being furnished as Exhibit 99.1 hereto.

The information in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed ?filed? for purposes of Section 18 of the Securities Exchange Act of 1934 (the ?Exchange Act?) or otherwise subject to the liabilities under such section, and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, or the Exchange Act.

Item 9.01. Financial Statements and Exhibits.

Exhibit No.


99.1 Investor Presentation dated March 2020


Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Cocrystal Pharma, Inc.

Dated: March 4, 2020 By: /s/ James Martin
James Martin
Chief Financial Officer  

105 Postings, 607 Tage GalacticaPlans to Advance Coronavirus Program

09.03.20 18:38
March 6, 2020

... Given the global threat of COVID1-9, our primary goal is to advance our Coronavirus program into preclinical development.  

1458 Postings, 2219 Tage Bezugs_RechtNEWS eben raus collaboration with Merck

30.03.20 12:22
Cocrystal Pharma Reports 2019 Financial Results and Outlines Expected Value-Driving Milestones for 2020  

8435 Postings, 1592 Tage VassagoCOCP 1.00$

16.04.20 14:33

40999 Postings, 2844 Tage wallander$1.40 baut sich langsam Druck auf :-)

13.06.20 13:46
Angehängte Grafik:
cocp_(2).png (verkleinert auf 47%) vergrößern

1384 Postings, 951 Tage BananiSoooo, bin mal mit einer kleinen Position

14.07.20 18:33
dabei, schauen wir mal wo die Reise hingeht, GLTA.  

1384 Postings, 951 Tage Banani08.07.20: Cocp initiated with a Buy at H.C....

19.07.20 09:43
Cocrystal Pharma initiated with a Buy at H.C. Wainwright

H.C. Wainwright analyst Raghuram Selvaraju initiated coverage of Cocrystal Pharma with a Buy rating and $5 price target. The company utilizes a "unique" proprietary co-crystallization platform to design novel small molecules aimed at well-known molecular targets within multiple viruses, Selvaraju tells investors in a research note. The analyst assumes a partnership to commercialize CC-31244, with royalties of 12%-20% payable to Cocrystal on net sales of the drug.

Read more at:  

1384 Postings, 951 Tage BananiAfter Hours - $2.82 - Vol. 7Mio.

04.08.20 06:01

1384 Postings, 951 Tage BananiPre-Market schon $3.50 - Vol. 876.6K

04.08.20 10:56

Riecht nach News, wieder auf das richtige Pferd gesetzt.  

11 Postings, 444 Tage yallenews

04.08.20 13:29
Hallo zusammen,

möglich das es sich um diese Meldung von gestern handelt ?

1384 Postings, 951 Tage BananiNews vom 04.08.2020 - Cocrystal Pharma Announces..

04.08.20 16:13
Cocrystal Pharma Announces the Publication by Collaborators of Positive Data Demonstrating Potent In Vitro Inhibition Against Coronavirus in Science Translational Medicine Journal  

8435 Postings, 1592 Tage VassagoCOCP 1.00$ (vorbörslich -26%)

27.08.20 10:35

1743 Postings, 5833 Tage calimeraInvestor Presentation September 2020

05.09.20 09:41
I should have chosen another hobby to take up! This one is alot of work and way too addictive

1384 Postings, 951 Tage BananiSchöner Anstieg heute.

24.11.20 19:55
Denke es hat mit dem TipRanks Artikel zu tun:

Billionaire Steven Cohen Pulls the Trigger on These 2 Penny Stocks  

1384 Postings, 951 Tage BananiVorbörslich geht die Post ab

25.11.20 11:58

1384 Postings, 951 Tage BananiAfter Hours - $1.67 - Vol. 395.56K

26.11.20 10:54

1384 Postings, 951 Tage BananiAfter Hours- $2.09 - 227.49k

28.11.20 09:39
Für einen Freitag ein schöner Endkurs, die Reise geht weiter, imo.  

1384 Postings, 951 Tage BananiWas für ein Endspurt

18.12.20 21:56

1384 Postings, 951 Tage BananiCocrystal Pharma Selects Lead

22.12.20 14:38
Compound for Further Development Against Coronaviruses

CDI-45205 holds potential as a therapeutic and as a prophylactic to protect against coronavirus transmission, including SARS-CoV-2  

1384 Postings, 951 Tage BananiVorbörslich +30%

24.12.20 12:27

656 Postings, 302 Tage DronatiaLöschung

30.12.20 07:15

Zeitpunkt: 30.12.20 11:26
Aktion: Löschung des Beitrages
Kommentar: Regelverstoß



1384 Postings, 951 Tage BananiNews

19.01.21 14:43
Cocrystal Pharma Announces Further Development of Influenza A/B Antiviral Compounds by Merck under Exclusive Worldwide License and Collaboration Agreement

... announces it has completed all research obligations under the Merck exclusive worldwide license and collaboration agreement, and that Merck is now solely responsible for further development of the influenza A/B antiviral compounds that were discovered using Cocrystal?s unique structure-based technologies and Nobel Prize-winning expertise.

... Under the agreement announced in January 2019, Merck had an option for Cocrystal to perform up to 12 months of additional work if the initial two years of collaboration did not progress as expected. We are pleased our collaboration achieved its goals within the timeline and that there is no need for Merck to exercise the option. As this program advances, Merck is now responsible for funding continued development of the compounds.?

... Developing new, effective influenza antivirals represents a significant unmet worldwide medical need and is integral to our infectious diseases R&D strategy,? said Daria Hazuda, Ph.D., Vice President, Infectious Diseases Discovery, Merck Research Laboratories and Chief Scientific Officer, Merck Exploratory Science Center. ?We are pleased with the progress under our collaboration with Cocrystal and look forward to further development of the antiviral agents in the influenza A/B program at Merck.?

1384 Postings, 951 Tage BananiNews von gestern

04.05.21 15:53
Cocrystal Pharma Provides Update on its COVID-19 Antiviral Discovery and Development Programs  

Seite: Zurück
| 2 Weiter  
   Antwort einfügen - nach oben

  4 Nutzer wurden vom Verfasser von der Diskussion ausgeschlossen: WKN 0815, Balu4u, moneywork4me, Volkswirt